The QualityStocks Daily Friday, August 30th, 2024

Today's Top 3 Investment Newsletters

360 Wall Street(BNRG) $1.5500 +140.27%

Premium Stock Alerts(FCUV) $0.2689 +41.45%

QualityStocks(FAAS) $1.3000 +30.00%

The QualityStocks Daily Stock List

Focus Universal (FCUV)

QualityStocks, Prince Report, Financial Newsletter and The Street reported earlier on Focus Universal (FCUV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Focus Universal Inc. (NASDAQ: FCUV) is a firm focused on the development and manufacture of smart instrumentation platforms and devices.

The Firm has its headquarters in Ontario, Canada and was incorporated in 2012, on December 4th by Desheng Wang. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers around the world.

The enterprise’s offerings include a wireless sensor device dubbed Ubiquitor, which has a universal sensor node and gateway system that uses a computer or mobile device as the output display module that displays the readings of various sensor nodes. Its universal smart instrumentation platform (USIP) uses computers or mobile devices to communicate with smart devices, such as sensors, probes, instruments and controllers to monitor and control any functions. It also provides digital sensors and horticultural sensors. In addition to this, the enterprise offers filter and handheld meter products, including carbon filters, fan speed adjuster and HEPA filtration systems, as well as digital light and quantum parameters through distributors. Furthermore, the enterprise offers integration of houses, apartments, commercial complexes, and office spaces with visual, audio and control systems to integrate devices in the low voltage field, as well as partial equipment upgrade and installation services.

The company, which has 3 foundational patents granted and 13 provisional patents covering a broad spectrum of technologies, remains focused on better meeting evolving consumer needs, bolstering its overall growth and generating value for its shareholders.

Focus Universal (FCUV), closed Friday's trading session at $0.2689, up 41.4519%, on 316,841,346 volume. The average volume for the last 3 months is 3.914M and the stock's 52-week low/high is $0.15/$2.38.

Cingulate Inc. (CING)

QualityStocks, MarketBeat, MarketClub Analysis, FreeRealTime, Wealth Daily, The Stock Dork, PennyStockProphet, OTCtipReporter and InsiderTrades reported earlier on Cingulate Inc. (CING), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical firm that is engaged in developing, manufacturing and commercializing treatments for neurobiological and central nervous system disorders.

The firm has its headquarters in Morristown, New Jersey and was incorporated in 2013 by Matthew N. Brams, Raul R. Silva, Craig Steven and Shane J. Schaffer. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company develops next-generation pharmaceuticals which have been designed to improve the lives of patients suffering from conditions which are characterized by suboptimal treatment outcomes and taxing daily dosing regimens.

The enterprise uses its proprietary precision time-release drug delivery platform technology to develop its pipeline of pharmaceutical products. Its product candidates include dexmethylphenidate (CTx-1301) and dextroamphetamine (CTx-1302), which have been developed to treat ADHD (attention deficit/hyperactivity disorder). These two candidates both contain 3 releases of active pharmaceutical ingredient, combined into a small tablet dosage form. The candidates have been developed for the following core patient segments: adults (aged 18 and above), adolescents (aged 13-17) and children (ages 6-12). In addition to this, the enterprise also develops CTx-2103 for the treatment of anxiety disorders.

The company recently launched an IPO whose proceeds it intends to use for the research, development and pre-commercialization of its ADHD products and for a proof of concept study for its anxiety disorder treatment. The success and approval of these products will bring in more revenues as well as investors into the company, which will be good for its growth.

Cingulate Inc. (CING), closed Friday's trading session at $7.89, up 22.7061%, on 5,248,724 volume. The average volume for the last 3 months is 9,156 and the stock's 52-week low/high is $1.8001/$187.20.

SIFCO Industries (SIF)

StockEarnings, SmarTrend Newsletters, TradersPro, StocksEarning, StockMarketWatch, StreetInsider, QualityStocks, MarketBeat, Street Insider, PoliticsAndMyPortfolio.com, Money Morning and MarketClub Analysis reported earlier on SIFCO Industries (SIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SIFCO Industries Inc. (NYSE American: SIF) (FRA: SI7) is focused on the production, sale and marketing of machined components, sub-assemblies and forgings for the energy and aerospace markets.

The firm has its headquarters in Cleveland, Ohio and was incorporated in 1913. It serves consumers around the globe, with a focus on Europe and North America.

The company’s manufacturing facilities are located in Maniago, Italy; Orange County, California and Cleveland, Ohio. Most of its revenue is derived from its North American segment.

The enterprise’s processes and services include machining, heat-treating and forging. It provides original equipment and spare components for industrial and aircraft gas turbine engines; rotating components for helicopters; aircraft brakes and wheels; aircraft landing gear components; structural airframe components; steam turbine blades; and other industrial/commercial products. Its products range in size from about 2 to 1,200 pounds and are made of aluminum, titanium, stainless steel and steel. In addition to this, it offers non-destructive testing, surface treatment, heat treatment and select machining and sub-assembly of forged components. The enterprise serves both aftermarket and original equipment manufacturer customers, as well as the global airline and aerospace industries through its network of service, manufacturing and distribution centers in the Far East, Europe and the United States.

The company recently announced its latest financial results, with its CEO noting that they remained focused on serving consumers across the energy and aerospace markets, growing the company’s content on major platforms and seeking opportunities in adjacent markets which would be good for the company’s growth.

SIFCO Industries (SIF), closed Friday's trading session at $5.1336, up 15.6216%, on 42,411 volume. The average volume for the last 3 months is 93,346 and the stock's 52-week low/high is $2.82/$5.21.

Medicenna Therapeutics Corp. (MDNAF)

QualityStocks, TradersPro and StockEarnings reported earlier on Medicenna Therapeutics Corp. (MDNAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company based in Toronto, Ontario. It focuses on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a wide array of cancers. Medicenna Therapeutics lists on the OTC Markets Group’s OTCQB.

Medicenna Therapeutics is developing an innovative set of tunable Superkines™, which can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.

Supported by a US$14.1M non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna Therapeutics’ lead IL4-EC, MDNA55, has completed enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centers in the United States. MDNA55 has been studied in five clinical trials involving 132 patients. This includes 112 adults with rGBM.

MDNA55 has demonstrated compelling efficacy. Moreover, it has obtained Fast-Track and Orphan Drug status from the FDA (Food and Drug Administration) and FDA/EMA (European Medicines Agency) respectively. MDNA55 targets Temodar-resistant tumors. Delivery by CED infusion of MDNA55 bypasses the BBB (Blood Brain Barrier). Precision delivery achieves high doses without systemic exposure.

Medicenna also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; and MDNA109, an IL-2 agonist to treat cancer immunotherapies. The Company also develops MDNA209, an IL-2 antagonist for autoimmune diseases; and MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis. Furthermore, Medicenna develops MDNA132, an IL-13 agonist to treat solid tumors, and IL 13Ralpha2 chimeric antigen receptor T cell.

Medicenna Therapeutics Corp. (MDNAF), closed Friday's trading session at $1.85, up 15.0211%, on 154,073 volume. The average volume for the last 3 months is 87,054 and the stock's 52-week low/high is $0.151251/$2.20.

Independence Contract Drilling (ICDI)

We reported earlier on Independence Contract Drilling (ICDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Independence Contract Drilling Inc. (OTCQX: ICDI) is engaged in the provision of contract drilling services for natural gas and oil producers that target unconventional resource plays in the U.S.

The firm has its headquarters in Houston, Texas and was incorporated in 2011, on November 4th by Byron A. Dunn and Philip A. Choyce. It operates as part of the support activities for the mining industry. The firm mainly serves consumers in the United States and has five companies in its corporate family.

The company is focused on its operations in unconventional resources plays situated in various regions in Midland and Houston, in the state of Texas. Its business is dependent on the level of production activity and exploration by natural gas and oil firms operating in the U.S., and particularly in areas where it advertises its contract drilling services.

The enterprise operates and owns a fleet made up of drilling rigs. Its ShaleDriller rigs have been designed to accelerate consumer production profiles and cash flows from their economically impactful and demanding gas and oil properties. Its rig fleet comprises of about 28 AC (alternating current) powered rigs. Of this number, about 23 are included in the enterprise’s marketed fleet. Its rigs primarily operate in the Eagle Ford Shale, the Haynesville Shale and the Permian Basin.

The firm recently reported their financial results for 2021’s second quarter, with its CEO noting that the firm is focused on increasing demand of all its rigs in its operating basins. This move will not only bring in additional revenue into the firm but also extend its consumer reach, which will have a positive effect on the company’s growth.

Independence Contract Drilling (ICDI), closed Friday's trading session at $0.445, up 14.1026%, on 477,043 volume. The average volume for the last 3 months is 41,620 and the stock's 52-week low/high is $0.3501/$3.29.

Butler National Corp. (BUKS)

QualityStocks, TopPennyStockMovers, Marketbeat.com, MarketBeat, PoliticsAndMyPortfolio.com and FeedBlitz reported earlier on Butler National Corp. (BUKS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Butler National Corp. is a top manufacturer and provider of support systems for commercial and military aircraft.  The Company is also a recognized provider of management services in different business groups. These include  the gaming industry.  Butler is a leader in the growing global market for aircraft structural modification, maintenance, repair and overhaul (MRO). Listed on the OTCQB, Butler National  is based  in Olathe, Kansas.

The Company formed in 1968 through the merger of an aviation research firm owned by the Butler family and National Connector Corporation. Butler National combined resources of the two companies to develop one of the first commercial Area Navigation Systems (RNAV) used for airplane navigation. 

Butler’s subsidiaries include  Avcon  Industries, Inc.;  Butler Avionics, Inc.;  BCS Design, Inc.;  Boot Hill Casino & Resort;  The Stables  Casino; and  Butler National-Tempe.  Avcon  Industries  provides  aircraft owners and operators with products and services designed to satisfy special mission requirements, or enhance the utility of business jets and turboprops. 

Butler National’s Aerospace segment concentrates on the manufacturing of support systems for "Classic" commercial and military aircraft. This includes the Butler National TSD for the Boeing 737 and 747 Classic aircraft. In addition, this segment concentrates  on switching equipment for Boeing McDonnell Douglas Aircraft, weapon control systems for Boeing Helicopter, and performance enhancement structural modifications for Learjet, Cessna, Dassault, and Beechcraft business aircraft.

Boot Hill Casino & Resort  is  in Dodge City, Kansas. It  is home to the first state owned and operated casino gaming in Kansas. The Stables Casino is  a Class III gaming establishment in Miami, Oklahoma. The Miami Tribe and the Modoc Tribe owns it.

Butler National-Tempe operates in the Defense Contracting & Electronics industry. Butler’s Management Services segment includes temporary employee services, gaming services, and administrative management services. Butler Avionics’ services include  new installations and retrofits, to avionics, autopilot, instruments, as well as radar troubleshooting and repair. Furthermore, BCS Design is a full-service architectural firm.

Butler National Corp. (BUKS), closed Friday's trading session at $1.19, up 11.7371%, on 93,120 volume. The average volume for the last 3 months is 89,867 and the stock's 52-week low/high is $0.569/$1.23.

DigiAsia Corp. (FAAS)

We reported earlier on DigiAsia Corp. (FAAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DigiAsia Corp. (NASDAQ: FAAS) (NASDAQ: FAASW) (FRA: QJ6) is a holding firm focused on the development of an AI embedded finance platform.

The firm has its headquarters in Jakarta, Indonesia and was incorporated in 2017, on October 23rd by Alexander Steven Rusli. It operates as part of the software-infrastructure industry, under the technology sector. The firm primarily serves consumers in Indonesia.

The enterprise provides a B2B fintech platform for supply chain payments, bill payments, and branchless banking solutions for partners, merchants, and customers; QRIS Payment as a Service; digital wallets; Cash Management System for ERP systems that enable users to create a closed-loop cash management system; Digital Product & Billers, which allows users to purchase digital products or pay bills to multiple issuers or billers; and Remittance Product that enables users to transfer funds from their application cash-to-cash, cash-to-account, account-to-cash, and account-to-account. It also offers gold saving products; B2B Loan products for micro, small, and medium enterprises; Buy Now Pay Later; Cash in & Cash Out points; Virtual Card Number to generate a digital invoice for customers to accept payment over internet transactions; e-KYC module to Onboard new customers securely in compliance with regulations; KasPro Bank for Banks and FSI to utilize their networks of retail outlets onboarded as licensed digital banking agents to offer cash-in & cash-out points to serve micro small, and medium enterprises.

The company recently entered a strategic collaboration with PT Jalin Pembayaran Nusantara that will advance the penetration of financial inclusion to the underserved across Indonesia. This will, in turn, extend the company’s consumer reach while opening it up to new growth and investment opportunities.

DigiAsia Corp. (FAAS), closed Friday's trading session at $1.3, up 30%, on 476,114 volume. The average volume for the last 3 months is 19.633M and the stock's 52-week low/high is $0.93/$13.99.

Microsoft Corp. (MSFT)

The Street, InvestorPlace, Kiplinger Today, Zacks, The Online Investor, Daily Trade Alert, StockMarketWatch, Schaeffer's, StreetInsider, MarketClub Analysis, StreetAuthority Daily, Money Morning, Investopedia, TopStockAnalysts, Trades Of The Day, IT News Daily, InvestorGuide, Market Intelligence Center Alert, internetnews, Early Bird, MarketBeat, QualityStocks, Stocks to Buy Now, NetworkNewsWire, SeriousTraders, SmallCapRelations, PROFIT CONFIDENTIAL, The Motley Fool, Daily Wealth, Uncommon Wisdom, Top Pros' Top Picks, internet, Wealth Insider Alert, Louis Navellier, Flagler Financial Group, Daily Market Beat, ProfitableTrading, Investor Guide, Cabot Wealth, Street Insider, The Wealth Report, Barchart, The Street Report, INO Market Report, CNBC Breaking News, Wyatt Investment Research, StocksEarning, Dividend Opportunities, SiliconValley, SmarTrend Newsletters, Daily Profit, StrategicTechInvestor, MarketWatch, Money and Markets, Insider Wealth Alert, GorillaTrades, Investors Alley, CustomerService, TipRanks, Stansberry Research, iStockAnalyst, INO.com Market Report, TradingAuthority Daily, Trading Markets, FreeRealTime, The Growth Stock Wire, Wealth Daily, Investment U, TheStockAdvisors, WStreet Market Commentary, Marketbeat.com, Investing Daily, Willy Wizard, Total Wealth, Greenbackers, Wall Street Daily, Energy and Capital, AllPennyStocks, TheStockAdvisor, Money Wealth Matters, Eagle Financial Publications, Daily Markets, DividendStocks, Contrarian Outlook, Trade of the Week, Market Intelligence Center, Investiv, SmallCap Network, Penny Stock Buzz, Dynamic Wealth Report, Shah's Insights & Indictments, Darwin Investing Network, StockEarnings, Market Authority, Trader Prep, FeedBlitz, Forbes, FNNO Newsletters, Power Profit Trades, The Night Owl, Investor Update, Wall Street Elite, SmallCapVoice, The Daily Market Alert, Daily Dividends, Short Term Wealth, TraderPower, BullDogReporter, TradingMarkets, Stockhouse, Stock Up Featured, Trading Concepts, StockTwits, Jon Markman’s Pivotal Point, Inside Investing Daily, Coattail Investor, The Trading Report, Investing Lab, The Best Newsletters, Bourbon and Bayonets, Options Elite, CRWEFinance, PennyOmega, InvestorsObserver Team, Wall Street Greek, InvestmentHouse, Investing Futures, Investment House, DrStockPick, The Weekly Options Trader, Super Stock Investor, TheOptionSpecialist, ChartAdvisor, Traders For Cash Flow, MarketMovingTrends, MarketArmor.com, Momentum Traders, 24/7 Trader, The Stock Dork, YOLOTraderAlerts, InsiderTrades, PennyToBuck, Momentum Trades, Stocks To Watch, CRWEWallStreet, SmallCapNetwork, equities Canada, Todd Horwitz, Early Investing, BestOtc, StreetAlerts, Market Pulse, The Tycoon Report, Leeb's Market Forecast, Lebed.biz, Untapped Wealth Online, InvestorIntel and Visual Capitalist reported earlier on Microsoft Corp. (MSFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Creative expression has for the longest time been thought to be unique and not vulnerable to disruption by advancing technology. We have seen creators flock to different platforms over the last couple of years, with more of them creating, sharing and publishing their user-generated content.

The rise of generative artificial intelligence (AI) threatens to disrupt this flourishing industry and modify the way content is produced. Using artificial intelligence models and simple prompts, any person can produce high-quality audio, images, video and more. With content generated by artificial intelligence becoming more popular, it remains unclear what impact this will have on the creator economy.

Some expect it to result in enhanced creativity, with more content creators adopting artificial intelligence to improve their productivity and performance. A good example of a model that can do this is Copilot, a coding assistant developed by GitHub to help developers create code.

In this context, AI won’t be a threat to individuals in the creative industry but, rather, will support them in doing their jobs better.

Others hold the opinion that the use of AI may, in the future, lead to these models having a monopoly on creativity. In this context, human writers, designers, coders and other skilled professionals are likely to be overshadowed by artificial intelligence models that can work faster in comparison to humans.

From a business angle, getting AI models to replace costly human creators is more profitable. It does lead to the loss of the livelihoods of many, while also negatively affecting creativity. This is mainly because outputs from these models are based on already existing content.

Reproducing similar content based on data these models are trained on does nothing to boost creativity while also infringing upon the rights of others. Examples of how this may go wrong are the current suits filed against Uncharted Labs and Suno, both of which are AI music generators. These algorithms have been trained on millions of videos on YouTube, with most of their output infringing others’ copyrights.

This brings into doubt AI’s ability to come up with original content, while also highlighting how the tech could affect innovation. With originality being a problem for AI, others expect that consumers will attune themselves to original human works and shun synthetic output by AI algorithms. Of the three scenarios discussed, this one seems to be the most likely to occur, seeing as humans will never stop creating and producing original content while algorithms can only copy and reproduce already existing ideas.

Companies that are leading the pack in AI innovation, such as Microsoft Corp. (NASDAQ: MSFT), need to think hard about the direction that user-generated content is going to take in the wake of their inventions, so that any unintended consequences with far-reaching effects can be avoided.

Microsoft Corp. (MSFT), closed Friday's trading session at $417.14, up 0.9730829%, on 24,308,324 volume. The average volume for the last 3 months is 12.682M and the stock's 52-week low/high is $309.45/$468.35.

PayPal Holdings (PYPL)

InvestorPlace, Kiplinger Today, The Street, MarketClub Analysis, Schaeffer's, MarketBeat, The Online Investor, Trades Of The Day, Daily Trade Alert, StocksEarning, Zacks, StreetInsider, StockEarnings, Market Intelligence Center Alert, Investopedia, The Wealth Report, Early Bird, Louis Navellier, GorillaTrades, Wealth Insider Alert, Top Pros' Top Picks, Barchart, StreetAuthority Daily, Marketbeat.com, Trading Tips, Daily Wealth, StrategicTechInvestor, MarketWatch, Money Wealth Matters, Cabot Wealth, INO Market Report, Trading Concepts, Uncommon Wisdom, QualityStocks, TopStockAnalysts, Profit Confidential, Daily Profit, CNBC Breaking News, Stansberry Research, Market Intelligence Center, Jon Markman’s Pivotal Point, FreeRealTime, Investors Alley, Money and Markets, Money Morning, ProfitableTrading, CustomerService, TipRanks, The Street Report, Wyatt Investment Research, SmallCapVoice, Smartmoneytrading, StockMarketWatch, TheOptionSpecialist, Investment House, Investiv, Investing Lab, The Stock Dork, InsiderTrades, Investing Signal, Earnings360, TradersPro, Chaikin PowerFeed, AllPennyStocks, Investing Daily, Stock Up Featured, Daily Dividends, Energy and Capital, 24/7 Trader, Traders For Cash Flow, Eagle Financial Publications, DividendStocks, SmallCapNetwork, Investing Futures, Wallstreet Journal, Total Wealth, Weekly Wizards, WStreet Market Commentary, Short Term Wealth, Penny Stock, BUYINS.NET, wyatt research newsletter, Average Joe Options, Schaeffer’s, Wall Street Daily, Rick Saddler, The Night Owl, Jim Cramer, Kiplinger’s Weekly Update, The Best Newsletters, Investor Guide, Market FN, InvestmentHouse, Equities.com, Street Insider, Trader Prep, MarketArmor.com, Milestone Capital Growth Portfolio, MarketClub, Insider Wealth Alert, INO.com Market Report, INO Traders Blog, Stock Market Watch, The Disciplined Trader and The 10-Minute Millionaire reported earlier on PayPal Holdings (PYPL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PayPal Holdings (NASDAQ: PYPL), a leading digital payments platform, has recently announced a significant expansion of its strategic partnership with Fiserv, Inc., aiming to enhance the checkout experiences across the United States. This collaboration is set to streamline the payment process, making it more efficient for users. PayPal, known for its robust payment solutions, is taking a step further in improving digital payment systems through this partnership, as highlighted by the official press release.

The announcement of this partnership comes at a time when PayPal’s stock is experiencing fluctuations in the market. Currently, PYPL is trading at $72, marking a decrease of $1.16 or approximately 1.59%. This decline is observed amidst a trading day where the stock saw a low of $71.82 and a high of $73.69. Despite these daily fluctuations, PayPal’s strategic moves, such as the partnership with Fiserv, are aimed at long-term growth and stability in the digital payments sector.

Over the past year, PayPal’s shares have navigated through highs and lows, with a record low of $50.25 and peaking at $73.93. These figures reflect the volatile nature of the stock market, yet PayPal’s strategic initiatives, like the one with Fiserv, demonstrate the company’s commitment to innovation and enhancing user experiences. With a market capitalization of about $73.61 billion and a trading volume of 3,730,316 shares on the NASDAQ exchange, PayPal remains a significant player in the digital payments industry.

The partnership between PayPal and Fiserv is not just a testament to PayPal’s dedication to improving payment processes but also an indicator of the company’s resilience in the face of market fluctuations. As PayPal continues to expand its global partnerships and enhance its services, it remains focused on its mission to democratize financial services and make digital payments accessible to all. This strategic move is expected to bolster PayPal’s position in the market, despite the current challenges reflected in its stock performance.

To view the company’s latest earnings release, visit https://ibn.fm/9vHGy

About PayPal

PayPal has been revolutionizing commerce globally for more than 25 years. Creating innovative experiences that make moving money, selling, and shopping simple, personalized, and secure, PayPal empowers consumers and businesses in approximately 200 markets to join and thrive in the global economy. For more information, visit www.PayPal.com.

PayPal Holdings (PYPL), closed Friday's trading session at $72.43, off by 0.997813%, on 9,634,963 volume. The average volume for the last 3 months is 43.003M and the stock's 52-week low/high is $50.25/$73.93.

Marathon Digital Holdings Inc. (MARA)

MarketClub Analysis, Schaeffer's, InvestorPlace, QualityStocks, INO Market Report, StockMarketWatch, MarketBeat, StockEarnings, StocksEarning, TradersPro, Early Bird, Zacks, Investors Underground, InvestorsUnderground, BUYINS.NET, The Online Investor, Lebed.biz, Trades Of The Day, The Street, FreeRealTime, TraderPower, Marketbeat.com, Daily Trade Alert, 360 Wall Street, Premium Stock Alerts, DailyMarketAlerts, BillionDollarClub, PoliticsAndMyPortfolio, CryptoCurrencyWire, TopPennyStockMovers, Wall Street Mover, Kiplinger Today, FeedBlitz, Wealth Insider Alert, Investment House, The Wealth Report, StreetAuthority Daily, MarketClub Options, Eagle Financial Publications, DreamTeamNetwork, Trading Pub, TradingPub, Wealth Daily, Barchart, AllPennyStocks, DividendStocks, Inside Trading, Promotion Stock Secrets, Investment News Daily, Street Insider, StockOodles, Jeff Bishop, Lance Ippolito, Stock Beast, Stock Analyzer, Rick Saddler, RedChip, ProsperityPub and StreetInsider reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The U.S. Securities and Exchange Commission (SEC) approved 12 and 9 Bitcoin and Ether spot exchange-traded funds (ETFs), respectively, this year. Understanding the distinctions between futures and spot cryptocurrency exchange-traded products (ETPs) is crucial for investors to navigate the ever-evolving world of crypto investments.

In traditional finance, often called “tradefi,” a crypto spot ETF is designed to directly hold the underlying digital currency, such as Ether or Bitcoin. When investors buy shares in a spot ETF, they are essentially purchasing a stake in the actual cryptocurrency. This framework replicates the real-time pricing of the crypto without requiring investors to handle the digital assets themselves. This streamlines the investment process by removing the need for investors to create an account on a crypto exchange or learn how to use a noncustodial wallet.

The Spot ETFs are traded on well-known stock exchanges such as CBOE, NASDAQ and NYSE. These platforms offer greater liquidity and come under stringent regulatory oversight, making them attractive to institutional investors that may be cautious about directly holding cryptos due to the associated risks.

Currently, there are 12 Bitcoin spot ETFs available in the United States, including tickers such as BTCO, DEFI, BTCW, EZBC, BRRR, HODL, BITB, ARKB, FBTC, BTC, GBTC and IBIT. Ether’s spot ETFs include CETH, QETH, EZET, ETHV, ETHW, FETH, ETHA, ETH and ETHE.

On the other hand, futures crypto ETFs operate differently. These ETFs do not hold the cryptocurrency itself. Instead, they invest in futures contracts, which are agreements to sell or buy an asset at a predetermined price on a specified future date.

Futures ETFs track the expected future price of the crypto rather than its current market value. This difference can lead to variations between the ETF’s price and the actual spot price of the cryptocurrency. These disparities could result from things such as contract roll fees and certain market circumstances that impact the performance of the futures contracts, including backwardation or contango.

Some of the leading Ether and Bitcoin and futures ETFs in the U.S. include BETE, EFUT, EETH, BITS, XBTF, BTF and BITO.

When choosing between futures and spot ETFs, investors must consider the varying cost structures and risk profiles of each. Spot ETFs offer direct exposure to the crypto’s market value but require trust in a custodian to securely manage the assets. While futures ETFs eliminate these custody issues, they nevertheless carry the associated complications of the futures market, such as the possibility of tracking errors and additional expenses for rolling contracts.

The choice between these two categories of ETFs ultimately comes down to an investor’s financial objectives and risk tolerance. For investors who are squeamish about directly or indirectly owning crypto, stocks of other industry players, such as mining companies, including Marathon Digital Holdings Inc. (NASDAQ: MARA), can be studied as another way to benefit from this growing industry.

Marathon Digital Holdings Inc. (MARA), closed Friday's trading session at $16.7, off by 1.7069%, on 31,089,257 volume. The average volume for the last 3 months is 2.926M and the stock's 52-week low/high is $7.16/$34.09.

Riley Financial Inc. (RILY)

InvestorPlace, Schaeffer's, InsiderTrades, The Online Investor, The Wealth Report, MarketBeat, Daily Trade Alert, StreetInsider, Marketbeat.com, TraderPower, Wealth Insider Alert, MarketClub Analysis, DividendStocks, BUYINS.NET, StreetAuthority Daily, The Street, Top Pros' Top Picks, Trades Of The Day and StockMarketWatch reported earlier on Riley Financial Inc. (RILY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Riley Financial Inc. (NASDAQ: RILY) is currently in a big financial hole that it dug itself after cofounder B. Riley got involved with a friend’s business ventures. The company, which was founded more than 25 years ago, had its stock collapse after a federal investigation on Brian Khan, a close confidant and business partner of Riley.

So, where did all this begin? Well, in November 2023, Khan was under federal investigation after the implications of a failed hedge fund that resulted in losses of millions of dollars. Khan denied these allegations, which saw his friend, Riley, supporting and defending him throughout the mess. However, this wavering support cost Riley and B. Riley Financial a lot. The U.S. Securities Exchange Commission (SEC), issued a subpoena to Riley and the company, which sent its stock plummeting, resulting in one of the biggest losses the company has experienced in years.

Adding to the turmoil was Riley’s attempt to make the Financial Service Provider a privately held company without really having the right financial backing. Riley, with a 24% stake in the company that made him the biggest shareholder, wrote a vague letter to the board expressing how he would like to salvage the company. Because of the vagueness of the letter, the investors were not convinced, resulting in the company, once valued at $2.45 billion, becoming a shadow of its former self.

One of the investors of B. Riley Financial recently shared that they were pulling out of the company and advised others to do the same. John Lekas, chief executive and senior portfolio manager at Leader Capital Corp. shared the following: “It was a solid operating company — I’m not sure how they veered so far off course. If you’re serious about making an offer, involve your legal team and get SEC approval. Now is the time to act with urgency.”

But B. Riley Financial, despite the setbacks, has played an important role in the financial landscape, especially as a middle-level company often overlooked by big investment banks. From selling stock and raising debt to wealth management, the Los Angeles-based company provides a range of services. However, its involvement with Khan’s business ventures put the company in a precarious situation.

Inside B. Riley Financial, there have been other challenges that have led to many questioning their confidence in the company. The company’s work culture, long hours, and not-so-great pay have made many junior bankers feel the pinch. What’s more, there have been concerns about business models laden with debt and weak internal controls. Along with Khan’s issues, these challenges have eroded confidence in the company’s stability.

As the SEC continues its investigation into the company known for investment banking, the future of the company hangs in the balance. In the meantime, all eyes are on Riley and his team to see the next step they take.

Riley Financial Inc. (RILY), closed Friday's trading session at $4.915, off by 10.3102%, on 2,720,253 volume. The average volume for the last 3 months is 2.281M and the stock's 52-week low/high is $4.51/$52.7398.

SNDL Inc. (SNDL)

StockEarnings, Schaeffer's, InvestorPlace, QualityStocks, StocksEarning, MarketBeat, Trades Of The Day, BUYINS.NET, Daily Trade Alert, The Street, Kiplinger Today, StreetInsider, CannabisNewsWire, The Online Investor, FreeRealTime, Early Bird, TheoTrade, Prism MarketView, CNBC Breaking News, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new study backed by the National Football League (NFL) sheds light on the increasing acceptance of therapeutic marijuana in sports while also highlighting the significant challenges posed by federal restrictions. These limitations continue to hinder research efforts, leaving a gap in understanding both the risks and benefits associated with cannabinoid use among athletes. The closing of this knowledge gap is an urgent matter, according to the report.

The study notes that, largely due to prohibition, healthcare providers lack sufficient understanding of a substance that is becoming more widely available for both recreational and therapeutic use.

The NFL committed $1 million in 2022 to studies examining the potential of cannabis to reduce pain and prevent concussions. This funding supported clinical research investigating the dosage of CBD and its potential as a substitute for opioids, in addition to the current investigation.

The study’s authors highlight the importance of education as a proven tool for reducing harm. “While there are ongoing efforts to educate the public on the risks of cannabinoids, equivalent efforts must be made to investigate and understand their benefits,” the 27-page paper argues.

The paper, which acknowledges both potential advantages and hazards for athletes using marijuana therapeutically, mostly evaluates existing literature. The authors warn against the dissemination of false information and unfavorable preconceptions that continue to impede the public’s understanding of cannabis and recommend a fair and impartial approach to sharing these findings.

The study highlights that concentrating only on negative messages runs counter to the positive experiences that many people who use cannabis products have had, which undermines public confidence in health authorities. Further, the study also discusses how the public’s comprehension of cannabinoid medicines is impeded by the cannabis industry’s emphasis on recreational usage. The industry’s commercial orientation, which permeates legal and political discourse, further blurs the discussion about the possible health advantages of cannabis products.

To truly serve the public, policymakers need to prioritize evidence-based studies, according to the study’s authors. However, this requires overcoming complex regulatory barriers that currently make it nearly impossible to conduct research on real-world cannabis products outside of studies funded by commercial interests.

One of the primary hurdles identified by the report is the limited availability of rigorous studies. The researchers note that many existing studies on humans have significant limitations in design and applicability. Variations in the types of cannabinoids studied, participant demographics and administration methods make it difficult to draw broad conclusions. As such, the authors advise caution when interpreting these findings, because they may not apply to other populations or different cannabinoid formulations.

The report also characterizes the existing cannabis laws and guidelines in sports as ambiguous and contradictory. The researchers urge politicians, medical experts and athletes to be better informed about the possible advantages and disadvantages of cannabis. The research makes the case that by addressing these problems, the sports community can promote a more knowledgeable and fair conversation on cannabis usage in sports.

As the misconceptions and stigma associated with marijuana use by athletes dissipates, many more are likely to use the products made by entities such as SNDL Inc. (NASDAQ: SNDL) to help in the management of the different physiological and mental-health challenges they face as a result of the rigors of the sports they participate in.

SNDL Inc. (SNDL), closed Friday's trading session at $1.97, up 1.0256%, on 1,206,079 volume. The average volume for the last 3 months is 7.27M and the stock's 52-week low/high is $1.30/$2.93.

The QualityStocks Company Corner

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals' (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. "The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal," reads a recent article. "The report highlights a 5.4% revenue increase in the edible market, with total sales reaching $2.097 billion. This growth is attributed to innovative developments in minor cannabinoid products. Among edible products, gummies demonstrated robust sales, while minor cannabinoid-infused edibles experienced an impressive 47% year-over-year growth, totaling $391 million in sales."

To view the full article, visit https://cnw.fm/fTU46

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Friday's trading session at $0.3549, up 2.9292%, on 523,483 volume. The average volume for the last 3 months is 25,404 and the stock's 52-week low/high is $0.1207/$2.08.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

Autism spectrum disorder, commonly referred to as autism, is a neurodevelopmental disorder that affects how a person interacts with others, as well as how they learn, communicate and behave. This disorder's symptoms usually appear in the first two years of an infant's life and often present as repetitive behaviors and restricted interests. A new study led by researchers at Yale has found a pair of neurodevelopmental abnormalities that may be associated with autism, with their differences being influenced by brain size. The researchers determined that these abnormalities arose just weeks after the brain started developing. The study's co-senior author was Dr. Flora Vaccarino of the Department of Neuroscience, Yale University. The study was co-led by Jessica Mariani, Feinan Wu and Alexandre Jourdon, all from Vaccarino's laboratory at the school of Medicine. The researchers' findings were reported in the "Nature Neuroscience" journal. As more teams, such as the team at PaxMedica Inc. (OTC: PXMD), continue to work to break new ground in the way autism is currently treated, patients can look forward to a time when effective formulations will be widely available to deliver the clinical outcomes that they long for.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Friday's trading session at $0.21495, up 3.0046%, on 730 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.08/$.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Over the past two months, the Copper Monthly Metals Index dropped 4.5%. While a strike at the Escondida mine managed to keep the price of the red metal afloat in the first weeks of this month, the red metal's price continues to decrease, dipping 5.7% below its July price. The mine, located in Chile and owned by BHP, accounts for about 5% of copper globally. Protests over pay led to a strike, which ended after the union signed a new three-year deal. Community backlash has also seen the Cobre Panama copper mine owned by First Quantum halt its operations. Additionally, the Las Bambas mine in Peru has been dealing with blockades as communities pressure mining companies to increase their support. Experts believe, however, that as more countries impose restrictions on products and materials from China, the country's demand for metals such as copper will face problems, especially if consumer demand doesn't improve. While the immediate future of the copper market remains uncertain, copper-exploration companies such as Torr Metals Inc. (TSX.V: TMET) can take comfort in the knowledge that in the long run, the demand for copper is projected to keep growing due to the ongoing clean-energy transition and the needs of other industries that require increasing amounts of the metal.

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Friday's trading session at $27.815, off by 0.518598%, on 2 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $24.01/$31.90.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

With a focus on the global horizon, Software Effective Solutions (OTC: SFWJ) has a vision of building its partner companies into one of the world's most advanced cannabinoid production and processing organizations. "MedCana has taken the first step in achieving that global mission. Recognizing that ideal climate conditions produce a better yield, the company announced that it has ‘searched the world over, and believes the Antioquia Valley, near Medellin [Colombia], is the perfect location to begin initial rollout of technology and production," reads a recent article.

"We are partnering with companies [in the valley] to begin implementation of our technology and tools with our partners," the company announced. "The 6,900-foot elevation and latitude provide optimal spring-like weather year-round. Natural rainfall and multiple artesian springs mean perfect, clean water. The soils are rich and, combined with the long days of sunshine, we can complete four growth cycles per year. This means access to highest-quality, inexpensive, certified materials in order to produce the highest-grade pharmaceutical extracts needed by the top pharmaceutical companies in the world."

To view the full article, visit https://cnw.fm/fTrHn

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Friday's trading session at $0.015, up 7.1429%, on 20,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer's Disease ("AD") and Parkinson's Disease ("PD"), recently welcomed four seasoned professionals to its executive team. "Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to the company's mission of developing transformative therapies for neurodegenerative diseases. The combined expertise of Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen will enhance strategic initiatives, strengthen communications, refine statistical approaches, and ensure the highest standards of quality. The company looks forward to their invaluable contributions as it continues to advance its clinical programs and strives to make a meaningful impact on the lives of patients with Alzheimer's and Parkinson's."

To view the full article visit https://ibn.fm/TjnEM

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.
Recent Achievements

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Annovis Bio Inc. (NYSE: ANVS), closed Friday's trading session at $8.46, off by 4.0816%, on 110,069 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"). "Clene's lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+') pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions," a recent article reads. "Clene has conducted extensive clinical trials to evaluate the safety and efficacy of CNM-Au8… With over 650 years of cumulative subject exposure, CNM-Au8 has shown a strong safety profile with no serious adverse events linked to the drug… Clene is gearing up for phase three programs for both ALS and MS. The company's innovative approach, backed by strong intellectual property with over 150 patients worldwide, positions it as a leader in addressing neurodegenerative diseases."

To view the full article, visit https://ibn.fm/0Ug43

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Friday's trading session at $5.27, off by 2.0446%, on 23,504 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$15.57.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech recently issued new unregistered warrants and closed on an exercise of certain existing warrants, raising approximately $2.3 million in aggregate gross proceeds

The company plans to use the proceeds of the warrant exercise to continue with its rollout of the Evolve(TM) product line (Evolve Rat and Evolve Mouse), the industry's only soft bait product line to control rodent populations by restricting fertility

The company's Evolve products, controlling rodents through rodent birth control versus poisons, represent safer alternatives to second-generation rodenticides, which threaten numerous species that ingest poisoned rodents, contaminated feces, contaminated soils, and sometimes the poisoned baits themselves

The U.S. Environmental Protection Agency is expected to come up with tighter regulations on second-generation poisons, positioning SenesTech for continued growth as demand increases

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, recently issued new unregistered warrants to purchase up to an aggregate of 1,011,004 shares of common stock at $4.35 per unit in a private placement. The company also closed on an exercise of certain existing warrants to purchase 505,502 shares of its common stock at a reduced exercise price of $4.60 per unit, raising approximately $2.3 million in aggregate gross proceeds. SenesTech intends to use the net proceeds from this transaction for working capital and general corporate purposes (https://ibn.fm/o12H7).

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Friday's trading session at $3.15, off by 3.0769%, on 9,041 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.65/$78.00.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

The company reports the successful production and completion of four workovers, along with increased gas production capacity, at its Black Sea asset

"This early return on our investment is a clear indicator of the field's robust production potential," notes the CEO

Trillion Energy International (CSE: TCF) (OTCQB: TRLEF), a company focused on oil and natural gas production for Europe and Türkiye, is marking a significant milestone in its strategic perforation program. The company reports the successful production and completion of four workovers, along with increased gas production capacity, at its Black Sea asset (https://ibn.fm/GEzxE).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Friday's trading session at $0.10075, off by 4.0476%, on 31,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0682/$1.175.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

Diego Morales, the secretary of state of Indiana, recently penned a cease-and-desist letter to BlackRock for securities fraud. Legislators in the state have already approved a bill that prohibits contentious strategies for environmental, social and governance (ESG) investment. In the letter, Morales accused the company of making misleading and false statements concerning its ESG funds. The letter was issued to the company through the state's securities division, which regulates the securities industry. It is almost identical to a letter issued by Michael Watson, Mississippi's state secretary. This announcement comes after BlackRock announced at the start of the year that it had grown support for proposals on corporate governance and was centering on the financial health of companies. From the latest report, the company backed 21% of such resolutions in the period. This is an 11% increase from corporate governance resolutions BlackRock backed 12 months earlier. As more companies such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) make ESG a normal part of their operations, efforts to fight this transition are likely to lose steam since the benefits of the transition will speak for themselves.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Friday's trading session at $0.067, off by 4.4223%, on 2,100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.1028.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

As the world races to transition away from fossil fuels, such as oil and natural gas, to renewable alternatives such as solar, innovation will be key to ensuring that the young green-energy industry has a future. Dozens of countries have already made significant progress in the transition, particularly in Europe, and the costs involved in building solar photovoltaic (PV) modules have dropped by more than 95% over the past several decades. Solar energy accounts for the majority of the world's green-energy capacity, followed by wind, thermal, hydropower and nuclear energy. While scientists are working hard to optimize solar technology and convert more of the sun's energy to electricity, additional technologies are needed to ensure we can take full advantage of solar energy. Both smart and refurbished transformers reduce the risk of surges, voltage spikes and grid disruptions, improving the dependability and overall safety of solar-energy storage. These transformers are also scalable and adaptable, easily adapting to different voltage requirements, configuring large-scale or residential systems, and serving a variety of energy needs. Innovation is also playing out in developing novel energy sources as exemplified by various companies that are commercializing hydrogen-energy systems and other green-energy technologies, such as FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF).

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.0328, off by 3.8123%, on 343,812 volume. The average volume for the last 3 months is 568,356 and the stock's 52-week low/high is $0.0221/$0.07.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI (OTC: ECGI), a diversified holding company focusing on viticulture, luxury fashion and equestrian markets, last year invested in Pacific Saddlery Inc., a premier manufacturer of equestrian apparel, tack, equipment, and accessories. "The company intended to carve out an operating niche in the luxury brands space, ensuring its products and services are synonymous with quality, elegance and an unrivaled value proposition for end users. ECGI in June buttressed the plans to realize this objective by signing a binding Letter of Intent (‘LOI') to acquire all outstanding shares of Pacific Saddlery. This move, the company noted, aligned with its objectives of expanding its presence in the luxury brands sector," a recent article reads. "Not long after, ECGI announced plans to launch a new line of ready-to-wear equestrian apparel under Pacific Saddlery's celebrated Allon brand. According to Nick Collins, president of Pacific Saddlery, this new collection is intended to elevate the standard of equestrian apparel… The launch comes when the global equestrian equipment and tack market and the larger equestrian market are poised for significant growth."

To view the full article, visit https://ibn.fm/TAAp3

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Friday's trading session at $0.0024, even for the day, on 25 volume. The average volume for the last 3 months is 433,451 and the stock's 52-week low/high is $0.0016/$0.0149.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

Golden Triangle Ventures (OTC: GTVH) previously announced a full-service freight brokerage business designed to significantly expand its logistics capabilities in a strategic move that aligns with its vision to assemble a strong portfolio. "The announcement comes as the company completed its acquisition of Cargo Management Group from T&K Zarro LLC and received the full financial commitment needed to launch the freight brokerage business. The Cargo Management Group acquisition includes a full-fledged logistics operation, brokerage business, licenses, and all associated assets… Golden Triangle Ventures also noted that, along with the acquisition, the company received full financial support from T&K Zarro to fund key components for the freight brokerage business, including state-of-the-art freight brokerage software and load board subscriptions to streamline all operations and improve service delivery. In addition, Cargo Management Group has noted key steps it is planning in order to ensure a successful launch," a recent article reads. "The acquisition of Cargo Management Group is a transformative step for GTV," said GTVH CEO Steffan Dalsgaard. "This deal provides a scalable business model that will support both Lavish Entertainment and the development of our future flagship project, Destino Ranch… Additionally, this helps move GTV toward its goal of becoming a highly profitable company with minimal to zero debt and a diverse asset portfolio."

To view the full article, visit https://ibn.fm/luJPM

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.